Affordable Access

deepdyve-link
Publisher Website

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Authors
  • Penel, Nicolas
  • Ray-Coquard, Isabelle
  • Bal-Mahieu, Christine
  • Chevreau, Christine
  • Le Cesne, Axel
  • Italiano, Antoine
  • Bompas, Emmanuelle
  • Clisant, Stéphanie
  • Baldeyrou, Brigitte
  • Lansiaux, Amélie
  • Robin, Yves-Marie
  • Bay, Jacques-Olivier
  • Piperno-Neumann, Sophie
  • Blay, Jean-Yves
  • Fournier, Charles
Type
Published Article
Journal
Targeted Oncology
Publisher
Springer-Verlag
Publication Date
Sep 01, 2014
Volume
9
Issue
3
Pages
273–277
Identifiers
DOI: 10.1007/s11523-013-0299-0
PMID: 24218035
Source
Medline
License
Unknown

Abstract

We have carried out a stratified phase II study of sorafenib (So) in patients with advanced angiosarcoma (n = 32) and epithelioid hemangioendothelioma (n = 13). This report concerns the correlative analysis of the predictive values of circulating pro/anti-angiogenetic biomarkers. Using the ELISA method (R&D Systems), circulating biomarkers (VEGF-A, in picograms per milliliter), thrombospondin-1 (TSP1, in micrograms per milliliter), stem cell factor (SCF, in picograms per milliliter), placental growth factor (PlGF, in picograms per milliliter), VEGF-C (in picograms per milliliter), and E-selectin (in nanograms per milliliter) were measured before So treatment and after 7 days. VEGF-A (mean value 475 vs. 541, p = 0.002), TSP1 (16 vs. 24, p = 0.0002), and PlGF (20.9 vs. 40.7, p = 0.0001) significantly increased during the treatment. Treatment did not affect the levels of SCF, VEGF-C, and E-selectin. Only two biomarkers were associated with better outcome as follows: VEGF-A and PlGF. Best objective response and non-progression at 180 days were associated with low level of VEGF-A at baseline (p = 0.04 and 0.03, respectively). There was a correlation between the circulating level of VEGF-A and time to progression (TTP) (r = -0.47, p = 0.001). Best objective response and non-progression at 180 days were not associated with baseline level of PIGF, but there was a correlation between the circulating level of PIGF at baseline and TTP. Low level of VEGF-A at baseline (<500) was significantly associated with better outcome.

Report this publication

Statistics

Seen <100 times